Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ultragenyx Pharmaceutical (RARE) Payables: 2016-2025

Historic Payables for Ultragenyx Pharmaceutical (RARE) over the last 10 years, with Sep 2025 value amounting to $40.6 million.

  • Ultragenyx Pharmaceutical's Payables rose 12.73% to $40.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $161.0 million, marking a year-over-year decrease of 9.99%. This contributed to the annual value of $38.8 million for FY2024, which is 7.97% down from last year.
  • Latest data reveals that Ultragenyx Pharmaceutical reported Payables of $40.6 million as of Q3 2025, which was up 18.49% from $34.2 million recorded in Q2 2025.
  • Over the past 5 years, Ultragenyx Pharmaceutical's Payables peaked at $59.8 million during Q2 2024, and registered a low of $15.6 million during Q3 2021.
  • Its 3-year average for Payables is $43.1 million, with a median of $41.0 million in 2024.
  • In the last 5 years, Ultragenyx Pharmaceutical's Payables surged by 152.50% in 2022 and then tumbled by 42.75% in 2025.
  • Over the past 5 years, Ultragenyx Pharmaceutical's Payables (Quarterly) stood at $17.1 million in 2021, then surged by 152.50% to $43.3 million in 2022, then dropped by 2.68% to $42.1 million in 2023, then decreased by 7.97% to $38.8 million in 2024, then climbed by 12.73% to $40.6 million in 2025.
  • Its last three reported values are $40.6 million in Q3 2025, $34.2 million for Q2 2025, and $47.5 million during Q1 2025.